Massive cut facing India's 'theoretical' Glivec price
This article was originally published in Scrip
India's latest drug price control measures could throw up a potentially peculiar situation for Novartis's anticancer, Glivec (imatinib), even as the Swiss multinational has probably yet to fully recover from the setback of April this year when the Supreme Court rejected a patent claim for the product in the country.
You may also be interested in...
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.